Rejection of the second allogeneic graft in a child with Fanconi anemia reversed by antilymphocyte globulin and donor lymphocyte infusion

Hematology Journal

Volumn 4, Issue 6, 2003, Pages 452-453

  Abdelkefi, Abderrahman ^a   Othman, T Ben ^a   Ladeb, S ^a   Torjman, L ^a   Abdeladhim, A Ben ^a  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

Author keywords

Donor lymphocyte infusion; Fanconi anemia; Rejection

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIBODY; METHOTREXATE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CASE REPORT; CHILD; CHIMERA; CLINICAL FEATURE; DOSE RESPONSE; FANCONI ANEMIA; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; MORTALITY; PANCYTOPENIA; PROGNOSIS; RISK FACTOR; SCORING SYSTEM;

ANTILYMPHOCYTE SERUM; CHILD; FANCONI ANEMIA; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVING DONORS; LYMPHOCYTE TRANSFUSION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0347135714     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200330     Document Type: Article

References (9)

1. Young NS, Alter BP. Clinical features of Fanconi's anemia. In: Young NS, Alter BP (eds.). Aplastic Anemia Acquired and Inherited. WB Saunders: Philadelphia, PA, 1994, pp 275-309.
2. Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86: 2856-2862.
3. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr Opin Hematol 1999; 6: 394-399.
4. Kohli-Kumar M, Morris C, De Laat C, Sambrano J, Masterson M, Mueller R et al. Bone marrow transplantation in Fanconi anemia using matched sibling donors. Blood 1994; 84: 2050-2054.
5. O'Donnell J, Roberts I, De la Fuente J, Daly P, New H, Dokal I et al. Successful second bone marrow transplant for Fanconi's anemia following escalation of conditioning. Br J Haematol 1997; 98: 772-774.
6. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host diseases immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
7. Gugliemi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
8. Aker M, Kapelushnik J, Pugatsch T, Naparstek E, Ben-Neria S, Yehuda O et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998; 20: 145-148.
9. Ljungman P, Lawler M, Lönnqvist B, Ringden O, Shanwell A et al. Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilympbocyte globulin and donor lymphocyte infusions. Bone Marrow Transplant 1996; 18: 1179-1181.